Background
Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) has been recognized as a phenotype of COPD that has clinical features of both asthma and COPD. 1 Patients with ACOS account for 15%-20% of COPD 2 with greater disease morbidity compared with those with COPD alone. 3, 4 Although the underlying pathobiology of ACOS is largely unclear, recent genomic studies have demonstrated a potential role of T H 2 inflammation 5 and eosinophil activation 6 in ACOS.
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Fractional exhaled nitric oxide (FeNO) has been used as a marker for T H 2-mediated airway inflammation in asthma. 7 FeNO gas is produced in the epithelial cells of the bronchial wall in response to interleukin-4 and -13, 8 which are produced locally by the T H 2 cells, mast cells, and eosinophils. Therefore, exhaled FeNO indicates the pro-inflammatory cytokine mechanisms in the pathophysiology of eosinophilic airway inflammation. Although studies have shown that the eosinophilic airway inflammation is a feature of ACOS, 5, 6 little is known about the FeNO levels in patients with ACOS in comparison with those with COPD alone.
To address this knowledge gap, a nationally representative sample was analyzed to determine the difference in FeNO levels between patients with ACOS and those with COPD alone in the US population. It was hypothesized that FeNO level is significantly higher in subjects with ACOS compared with those with COPD alone.
Methods
This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) from 2007 through 2012. Details of the study design, setting, and analysis may be found in the Supplementary material. The NHANES is a national survey that collects biologic samples on a representative sample of the US population, provided by the National Center for Health Statistics at the Centers for Disease Control and Prevention. 9 NHANES participants were sampled through a complex, multistage sampling methodology to ensure that the sample is nationally representative. Because the NHANES survey is a single-point interview, follow-up data are not available.
Participants were interviewed for demographics including age, sex, race/ethnicity, primary health insurance, smoking history, medical history, comorbidities, and health care utilization. In addition, participants underwent medical and physiologic examinations as well as laboratory testing. During the household interview survey, participants were asked whether they had taken medications in the past month for which they needed a prescription. Those who answered "yes" were asked to show the medication containers of all the products used to the interviewer. If no container was available, the interviewer asked the participant to verbally report the name of the medication. Written informed consent was obtained from all the participants, and the National Center for Health Statistics Research Ethics Review Board approved the protocol. The institutional review board of Massachusetts General Hospital approved this analysis.
All subjects aged $40 years with COPD, defined as a post-bronchodilator forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (FVC) ,0.70 with a history of smoking $100 cigarettes total in their life and with at least one of following symptoms, cough, sputum production, wheezing, and shortness of breath on exertion, were identified. 10, 11 In the NHANES, spirometry was conducted according to the American Thoracic Society recommendations. 12 Participants who met the following criteria were excluded from spirometry for safety reasons: current chest pain or pain with forceful expiration; current use of daytime supplemental oxygen; had recent surgery of the eye, chest, or abdomen; or had a recent heart attack, stroke, tuberculosis exposure, hemoptysis, a history of detached retina, or pneumothorax. Participants who underwent a "baseline" (pre-bronchodilator) spirometry were selected for follow-up "post-bronchodilator" spirometry if their baseline spirometry values indicated possible airflow obstruction. 10, 13, 14 The Global initiative of chronic Obstructive Lung Disease (GOLD) stage was defined on the basis of the post-bronchodilator spirometry parameters (ie, FEV 1 /FVC and FEV 1 percent of predicted). 10 Predicted FEV 1 was calculated on the basis of sex, age, and height according to a previous literature. 14 According to the literature, ACOS was defined as self-reported wheezing in past 12 months plus bronchodilator response (FVC increase of .200 mL and .12%) or self-reported physician diagnosis of asthma. 15 In sensitivity analysis, an alternative definition of ACOS was also useddefined by the presence of one major criterion or two minor criteria. 16 Major criteria were 1) history of asthma and 2) bronchodilator response of $15% and 400 mL; minor criteria were 1) history of hay fever, 2) bronchodilator responses to salbutamol of $12% and 200 mL, and 3) blood eosinophils $5%. The primary outcome was FeNO level (ppb). The unadjusted and multivariable linear regression models were fitted. Multivariable model adjusted for up to six confounders (age, sex, race/ethnicity, steroid use, medications for wheezing, and current smoking status) as the number of subjects with ACOS was relatively small. Given the known effects of smoking on FeNO levels, the models were stratified by current smoking status (yes/no). These analyses were repeated with the use of alternative definition of ACOS. The distinction between active-smokers and non-current smokers was ascertained through the NHANES question asking, "are you smoking currently?"
The receiver operating characteristic curves were drawn to evaluate the diagnostic value of FeNO for discriminating ACOS from COPD alone. To maximize the sum of sensitivity 
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FenO levels differ between aCOs and COPD alone and specificity for all the possible values of the cutoff point, the Youden index method was applied. Sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio were calculated and given with 95% confidence intervals. Statistical analyses were performed using Stata version 13.1 (StataCorp, College Station, TX, USA), accounting for the complex survey design.
Results
We identified 197 subjects with COPD in the NHANES. Overall, the mean age was 58 years and 69% were male. Of these, 23% met the primary criteria of ACOS while 28% met the alternative criteria of ACOS. The mean age of asthma diagnosis in ACOS group was 22 years. The body mass index and the prevalence of wheezing were higher in subjects with ACOS group compared with those with COPD alone. Between subjects with ACOS and those with COPD alone, most of demographic characteristics, medical history, pulmonary function test, or GOLD stage did not significantly differ (P.0.05), regardless of ACOS definition (Tables 1 and S1 Figure 1 ). After adjusting for potential confounders, the significant difference persisted (adjusted Figure S1 and Table 3 ).
The diagnostic value of FeNO to discriminate ACOS from COPD alone was not sufficient, with the area under the curve (AUC) of 0.63 (95% CI, 0.54 to 0.72; Figure 2 ). By using Youden index, the FeNO level $8.5 ppb was the best cutoff value for the maximum potential effectiveness of FeNO (sensitivity, 80.9%; specificity, 44.5%; positive likelihood ratio [LR+], 1.45; and negative likelihood ratio [LR-], 0.43). To maximize the diagnostic value for discrimination with a clinically meaningful value, the FeNO level $36 ppb was another cutoff value (sensitivity, 12.8%; specificity, 95.2%; LR+, 2.66; and LR-, 0.92). These diagnostic values did not change materially in the sensitivity analysis with the use of alternative definition of ACOS. The AUC was 0.63 (95% CI, 0.54-0.72; Figure S2 ), and the cutoff value using Youden 
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FenO levels differ between aCOs and COPD alone index was the FeNO level $8.0 ppb (sensitivity, 80.8%; specificity, 51.8%; LR+, 1.37; LR-, 0.47). To maximize the diagnostic value for discrimination with a clinically meaningful value, the FeNO level $36 ppb was another cutoff value (sensitivity, 11.5%; specificity, 95.4%; LR+, 2.3; LR-, 0.93).
Discussion
Although inflammation in COPD is thought to be driven primarily by neutrophilic inflammation, recent studies suggest the presence of T H 2-mediated airway inflammation in subsets of patients -for example, those with ACOS. Within the limited literature, Christenson et al demonstrated that, in patient with COPD, airway epithelial gene signatures of T H 2-mediated inflammation are associated with "asthma-like" features, favorable corticosteroid response, and increased disease severity. 5 Similarly, using a genome-wide association approach, Hardin et al reported an association between GPR65 (a gene involved in eosinophil activation) and COPD with physician-diagnosed asthma. 6 Along with these genomic studies, Donohue et al, in a two-center cross-sectional study, found higher FeNO levels in patients with COPD with an International Classification of Diseases-9 diagnosis code of asthma compared with those with COPD alone. 17 In addition, a small study in Japan reported that FeNO .35 ppb and evidence of atopy predicted improvement in FEV 1 with inhaled corticosteroids and long-acting beta agonist on airflow limitation in COPD. 18 Our results corroborate on these studies and extend them by demonstrating the difference in FeNO levels between patients with ACOS and those with COPD alone using nationally representative data with comprehensive clinical, physiological, and biological assessment.
Our study has several potential limitations. First, there is no universally accepted definition of ACOS. Nevertheless, with the use of two different, previously applied definitions of ACOS, 15, 16 consistent findings were observed. Second, there might be a misclassification and underreporting of subjects' medications (eg, systemic or inhaled corticosteroids), although the self-reported use of prescription medications was verified with prescription bottles. However, assuming that the frequency of misclassifications does not vary significantly between the two groups, this nondifferential misclassification would have biased our inferences toward the null. Third, some of the elderly subjects, particularly individuals $70 years, were not eligible for spirometry testing based on the NHANES protocol. Thus, our findings may have less generalizability to the elderly patients with COPD. In addition, the underrepresentation of subjects with severe GOLD stages might have overestimated the prevalence of ACOS in this study, although our estimate of the prevalence of ACOS was consistent with the previous literature (15%-20%). 2 Finally, as with any observational study, the significant difference in FeNO between the groups might be explained, at least partly, by unmeasured confounders.
Conclusion
In sum, these nationally representative data demonstrated that approximately one in four COPD subjects had ACOS, indicating the substantial public health burden of ACOS in the US. It was also found that FeNO level was significantly higher in subjects with ACOS compared with those with COPD alone, while the diagnostic value of FeNO to discriminate ACOS from COPD alone was not sufficient. Although the clinical role of FeNO in the identification of patients with ACOS requires further study, our findings should encourage researchers to investigate pathobiology of ACOS (eg, T H 2-mediated airway inflammation) and develop targeted therapeutic strategies (eg, anti-T H 2 therapies) for this important subtype of COPD.
